Atuiri C, Foster D, Li X, Hadidi D, Sokhn J
Eur J Case Rep Intern Med. 2024; 11(8):004760.
PMID: 39130063
PMC: 11313116.
DOI: 10.12890/2024_004760.
Huynh L, Swanson S, Cima S, Haddadin E, Baine M
Cancers (Basel). 2024; 16(10).
PMID: 38791977
PMC: 11120365.
DOI: 10.3390/cancers16101897.
Cao Y, Liu W, Gu D
Eur Arch Otorhinolaryngol. 2023; 280(8):3867-3875.
PMID: 37071145
DOI: 10.1007/s00405-023-07971-5.
Huynh L, Hwang Y, Taylor O, Baine M
Diagnostics (Basel). 2023; 13(6).
PMID: 36980436
PMC: 10047271.
DOI: 10.3390/diagnostics13061128.
Wen P, Wen J, Huang X, Wang F
J Clin Med. 2023; 12(4).
PMID: 36835849
PMC: 9962885.
DOI: 10.3390/jcm12041314.
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
Nyberg T, Brook M, Ficorella L, Lee A, Dennis J, Yang X
J Clin Oncol. 2022; 41(5):1092-1104.
PMID: 36493335
PMC: 9928632.
DOI: 10.1200/JCO.22.01453.
An appraisal of genetic testing for prostate cancer susceptibility.
Finch A, Clark R, Vesprini D, Lorentz J, Kim R, Thain E
NPJ Precis Oncol. 2022; 6(1):43.
PMID: 35732815
PMC: 9217944.
DOI: 10.1038/s41698-022-00282-8.
Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction.
Lin Y, Liu G, Liu C, Xie H, Wang X, Huang Y
Cancer Med. 2022; 11(15):2875-2885.
PMID: 35289508
PMC: 9359874.
DOI: 10.1002/cam4.4629.
Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.
Hong H, Liang D, Liu Q, Wu G, Sun R, Liu J
Quant Imaging Med Surg. 2022; 12(3):1750-1761.
PMID: 35284288
PMC: 8899971.
DOI: 10.21037/qims-21-365.
Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018.
Richards T, Dai S, Gray S, Hall I, Siegel D
Urol Oncol. 2022; 40(5):192.e19-192.e25.
PMID: 35236620
PMC: 9081142.
DOI: 10.1016/j.urolonc.2022.01.016.
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian N, Poveda J, Pineda-Lucena A, Puchades-Carrasco L
Cancers (Basel). 2022; 14(3).
PMID: 35158864
PMC: 8833769.
DOI: 10.3390/cancers14030596.
Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
Saidova A, Potashnikova D, Tvorogova A, Paklina O, Veliev E, Knyshinsky G
PLoS One. 2021; 16(5):e0251961.
PMID: 34019593
PMC: 8139512.
DOI: 10.1371/journal.pone.0251961.
Clinical utility of current biomarkers for prostate cancer detection.
Kim J, Hong S
Investig Clin Urol. 2020; 62(1):1-13.
PMID: 33381926
PMC: 7801171.
DOI: 10.4111/icu.20200395.
Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients.
Liu K, Huang G, Chang P, Zhang W, Li T, Dai Z
Sci Rep. 2020; 10(1):21376.
PMID: 33288828
PMC: 7721744.
DOI: 10.1038/s41598-020-78545-2.
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in : A Review of Secondary Prevention Guidelines.
Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E
J Oncol. 2020; 2020:9873954.
PMID: 32655641
PMC: 7322604.
DOI: 10.1155/2020/9873954.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri V, Knudsen K, Kelly W, Cheng H, Cooney K, Cookson M
J Clin Oncol. 2020; 38(24):2798-2811.
PMID: 32516092
PMC: 7430215.
DOI: 10.1200/JCO.20.00046.
A New Nomogram Allowing Physicians to Predict Patients at High Risk of Fever Occurring After Prostate Biopsy.
Xia H, Wang H, Chen L, Meng J, Zhou J, Liang C
Med Sci Monit. 2020; 26:e921350.
PMID: 32200388
PMC: 7111130.
DOI: 10.12659/MSM.921350.
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with primary urethral carcinoma: a population-based study.
Zi H, Gao L, Yu Z, Wang C, Ren X, Lyu J
Int Urol Nephrol. 2019; 52(2):287-300.
PMID: 31612421
DOI: 10.1007/s11255-019-02314-y.
A review of optimal prostate biopsy: indications and techniques.
Streicher J, Meyerson B, Karivedu V, Sidana A
Ther Adv Urol. 2019; 11:1756287219870074.
PMID: 31489033
PMC: 6713958.
DOI: 10.1177/1756287219870074.
Nomograms for estimating survival in patients with papillary thyroid cancer after surgery.
Liu G, Liu Q, Sun S
Cancer Manag Res. 2019; 11:3535-3544.
PMID: 31114382
PMC: 6497889.
DOI: 10.2147/CMAR.S194366.
